Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. Additionally we are shipping PCSK9 Kits (72) and PCSK9 Proteins (61) and many more products for this protein.
Showing 10 out of 155 products:
Human Polyclonal PCSK9 Primary Antibody for ChIP, IHC (p) - ABIN268772
Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. in Nature genetics 2005
Show all 10 references for 268772
Human Polyclonal PCSK9 Primary Antibody for EIA, WB - ABIN453778
McNutt, Kwon, Chen, Chen, Horton, Lagace: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. in The Journal of biological chemistry 2009
Show all 3 references for 453778
Human Polyclonal PCSK9 Primary Antibody for IHC, ELISA - ABIN185371
Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. in Journal of lipid research 2005
Show all 2 references for 185371
Human Polyclonal PCSK9 Primary Antibody for FACS, IHC (p) - ABIN391505
Shioji, Mannami, Kokubo, Inamoto, Takagi, Goto, Nonogi, Iwai: Genetic variants in PCSK9 affect the cholesterol level in Japanese. in Journal of human genetics 2004
Show all 2 references for 391505
Human Polyclonal PCSK9 Primary Antibody for FACS, IHC (p) - ABIN652320
Abifadel, Varret, Rabès, Allard, Ouguerram, Devillers, Cruaud, Benjannet, Wickham, Erlich, Derré, Villéger, Farnier, Beucler, Bruckert, Chambaz, Chanu, Lecerf, Luc, Moulin, Weissenbach, Prat, Krempf et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. ... in Nature genetics 2003
Show all 2 references for 652320
Human Polyclonal PCSK9 Primary Antibody for IF (p), IHC (p) - ABIN761831
Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. in Molecular medicine reports 2016
Human Polyclonal PCSK9 Primary Antibody for EIA, WB - ABIN569616
Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. in Proceedings of the National Academy of Sciences of the United States of America 2008
Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C-III (apoC3 (show APOC3 Antibodies)) and small dense low density lipoprotein cholesterol (sdLDL-C) showed significant interactions with current dyslipidemias, and were predictive in the screening.
Some loss of function variants in PCSK9 are associated with enhanced LDL cholesterol lowering response to statin therapy.
These observations suggest positive feedback interplay between SMC (show DYM Antibodies)-derived PCSK9 and mtDNA damage in the proinflammatory milieu involving mtROS. This interaction results in cellular injury, characterized by apoptosis-a hallmark of atherosclerosis.
PCSK9 level is not associated with systolic or diastolic blood pressure in hypertensives or normotensives, but it positively correlates with carotid intima-media thickness in hypertensives in univariate but not multivariate analyses, and further researches are needed.
results reveal that the tanshinone IIA modulates LDLR (show LDLR Antibodies) level and activity via down-regulation of PCSK9 expression in hepatic cells
This article reviews the functions and regulatory mechanisms of PCSK9. The effects of PCSK9 on the LDL receptor (show LDLR Antibodies), the relationship of this convertase with IDOL (show MYLIP Antibodies), and treatments currently available against hypercholesterolemia are also discussed. [review]
LC n-3 PUFA intake is associated with a lower risk of nonfatal MI in C-allele carriers of PCSK9 rs11206510 (n = 799) but not in non-C-allele carriers (n = 3188).
the zymogen form of PCSK9 adopts a structure that is distinct from the processed form and is unable to bind a mimetic peptide based on the EGF (show EGF Antibodies)-A domain of the LDLr (show LDLR Antibodies).
CRP (show CRP Antibodies) increased PCSK9 expression by activating p38MAPK (show MAPK14 Antibodies)-HNF1alpha (show HNF1A Antibodies) pathway, with a certain downstream impairment in LDL metabolism in HepG2 cells.
PCSK9 C-terminal domain (CTD) was found to be essential to induce LDLR (show LDLR Antibodies) degradation both upon its overexpression in cells or via the extracellular pathway.
AdipoR activation by agonists regulated PCSK9 expression and inhibits atherosclerosis in apoE (show APOE Antibodies)(-/-) mice.
Adeno (show ADORA2A Antibodies)-associated virus mediated infection with a mouse PCSK9 gain-of-function mutation is a rapid, easy, and efficient approach for inducing hypercholesterolemia and promoting abdominal aortic aneurysms in C57BL/6 mice infused with angiotensin II.
conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2 (show CA2 Antibodies)+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR (show LDLR Antibodies) degradation and promoting LDLR (show LDLR Antibodies)-dependent hepatic cholesterol uptake.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor (show LDLR Antibodies) Degradation.
PCSK9 increases hepatic lipid and lipoprotein production via apoE (show APOE Antibodies)- and LDLR (show LDLR Antibodies)-dependent mechanisms
Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating PCSK9.
binding of PCSK9 to GRP94 (show HSP90B1 Antibodies) protects LDLR (show LDLR Antibodies) from degradation likely by preventing early binding of PCSK9 to LDLR (show LDLR Antibodies)
The absence of PCSK9 results in a sex- and tissue-specific subcellular distribution of the LDLR (show LDLR Antibodies) and VLDLR (show VLDLR Antibodies), which is determined by estradiol levels.
This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
proprotein convertase subtilisin/kexin type 9
, convertase subtilisin/kexin type 9 preproprotein
, neural apoptosis regulated convertase 1
, subtilisin/kexin-like protease PC9
, convertase subtilisin
, neural apoptosis-regulated convertase 1
, proprotein convertase 9
, proprotein convertase PC9
, proprotein convertase subtilisin/kexin type 9 preproprotein
, Proprotein convertase 9
, Subtilisin/kexin-like protease PC9